[Antihypertensive and organ-protective action of a 36-week monotherapy with telmisartan in hypertensive patients].

Autor:	Petriĭ VV, Sergushkina NG, Brazhnik VA, Makolkin VI
Jazyk:	ruština
Zdroj:	Terapevticheskii arkhiv [Ter Arkh] 2008; Vol. 80 (12), pp. 13-6.
Abstrakt:	Aim: To study hypotensive effectiveness and organ-protective properties of telmisartan in patients with essential hypertension (EH). Material and Methods: The trial enrolled 33 patients with EH of stage II, blood pressure (BP) elevation of the first and second degree, with ultrasound-diagnosed left ventricular (LV) hypertrophy and/or increased thickness of intima-media complex (IMC) of the muscular-elastic vessels. The patients received 40-80 mg/day telmisartan monotherapy for 36 weeks. Hypotensive efficacy of the drug was assessed at 24-hr BP monitoring, a protective effect--at echocardiography and ultrasound duplex scanning of the vessels. Results: A 36-week telmisartan monotherapy significantly improved all the analysed parameters of 24-hr BP monitoring. LV myocardial mass reduced by 12.7%, index of this mass--by 12.9%. Overall thickness of intima-media of the muscular-elastic vessels (common carotid and femoral arteries) lowered by 11.9%. Conclusion: Long-term telmisartan monotherapy improves parameters of 24-hr BP monitoring, protects the heart and the vessels against remodeling, promotes reduction of LV hypertrophy and intimamedia thickness of muscular-elastic arteries.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu